What is Elucid?
Elucid is at the forefront of medical technology, developing and deploying uniquely interpretable and validated Artificial Intelligence (AI) to empower physicians in optimizing treatment strategies for patients suffering from cardiovascular disease. The company's advanced clinical insights are designed to facilitate precision medicine, offering a cost-effective approach to patient care. Notably, Elucid has achieved FDA-Clearance and CE-marking for its non-invasive software, which is capable of quantifying atherosclerotic plaque characteristics and comparing them to histopathology, including Lipid Rich Necrotic Core. This technological advancement positions Elucid as a key innovator in the diagnostic and treatment decision support sector.
How much funding has Elucid raised?
Elucid has raised a total of $45.2M across 3 funding rounds:
Grant
$696K
Series A
$8M
Private Equity
$36.5M
Grant (2014): $696K with participation from National Science Foundation
Series A (2021): $8M led by BlueStone Venture Partners, MedTex Ventures, University of Michigan, Checkmate Capital, Angel Physicians Fund, Willamette Valley Capital, IAG Capital Partners, and Global Health Impact Fund
Private Equity (2025): $36.5M, investors not publicly disclosed
Key Investors in Elucid
BlueStone Venture Partners
BlueStone Venture Partners is a life sciences venture capital fund that invests in innovative companies, particularly those outside traditional investment hubs. They focus on leveraging management skills and industry relationships to support early-stage ventures in life sciences and information technology.
Checkmate Capital
Checkmate Capital is a management consulting firm specializing in investments and advisory services, focusing on creating special situation investment opportunities across various sectors including biotechnology. They leverage cash flow generating assets and advisory expertise for long-term value creation.
Global Health Impact Fund
The Global Health Impact Fund is a clinician-founded venture capital fund that invests in early-stage healthcare companies at the intersection of medicine and technology, providing support through its extensive clinician network.
What's next for Elucid?
With the recent influx of major strategic investment, Elucid is well-positioned to accelerate its growth trajectory. The company is expected to leverage this capital to further enhance its AI platform, expand its clinical validation efforts, and broaden its market penetration within the cardiovascular disease sector. Future developments may include strategic partnerships with healthcare providers and research institutions to integrate Elucid's technology more deeply into clinical workflows, thereby solidifying its role in advancing precision medicine and improving patient outcomes. The company's focus on interpretable AI and FDA-cleared technology provides a strong foundation for sustained innovation and market leadership.
See full Elucid company page
